RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma
RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.
Related Articles
A Nuanced Understanding of Cellular Biology Advances Neuro-Oncology Practice: With D. Ross Camidge, MD, PhD; and Adrienne A. Boire, MD, PhD
Drs Camidge and Boire discuss Dr Boire’s path to becoming a physician-scientist and how cellular biology research can improve outcomes for patients with cancer.
An Assortment of Journal Abstracts to Enhance Oncology Care : Oncology Times
An abstract is unavailable.
Welcome! You are invited to join a webinar: AHNS Virtual Education Series: Recon ‘Round the World: Africa – “Mandibular and Maxillary Reconstruction”. After registering, you will receive a confirmation email about joining the webinar.
Presented by the AHNS Reconstructive Head & Neck Surgery Section Moderator: Chad Zender, MD, Professor Otolaryngology, Director Head and Neck Surgery, University Of Cincinnati AHNS…
Oncology Experts Preview Top Abstracts to be Shared at 2025 ASCO GI
Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.
Patient-Matched Tumor-Normal Sequencing
During our combined 35 years working to advance diagnostic capabilities for cancer—as a pathologist and as a bioinformatician, respectively—we’ve had the opportunity to help build…
OST-HER2 Extends 12-Month EFS in Osteosarcoma With Lung Metastases
OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years in recurrent, fully resected osteosarcoma and lung…
Youtube Icon
Optimizing Treatment Strategies for Localized and Advanced Genitourinary MalignanciesPresented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education.
Fox Chase Cancer Center Scientist Yash Chhabra Honored With NextGen Stars Award From American Association for Cancer Research
PHILADELPHIA (January 21, 2025) — Yash Chhabra, PhD, Assistant Professor in the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was recently…
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
Dr. Aditya Bardia presents real-world findings on elacestrant, demonstrating prolonged real-world progression-free survival (rwPFS) in ER+/HER2- advanced breast cancer patients across all clinically relevant subgroups,…
AI Use in Surgeries for Prostate Cancer May Help Standardize Outcomes
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.